Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Dollar General Corp. (DG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Dollar General Corp. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Dollar General Corp. trades at $116.28 (market cap $25.46B). The key difference: Dollar General Corp. is far larger — about 5.7× ACADIA Pharmaceuticals Inc.'s market cap, and Dollar General Corp. pays a 2.04% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | DG | |
|---|---|---|
Market Cap | $4.49B | $25.46B |
Sector | Health | Consumer Staples |
52-Week High | $28.06 | $156.26 |
52-Week Low | $20.06 | $95.94 |
Enterprise Value | $3.69B | $39.91B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Dollar General (DG) trades at $115.43, down 2.32% on the day, with technical indicators showing a neutral to bearish short-term bias. The stock has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.00 surpassing the $1.89 estimate. Fundamentals reveal steady revenue growth to $40.61 billion in 2025, though net income margin has compressed to 2.77%. Positive cash flow trends and a manageable debt-to-asset ratio of 20.03% support financial health.
The investment outlook is cautiously optimistic, driven by analyst consensus favoring a Buy rating with a $128.91 price target, implying ~12% upside. Key opportunities include margin expansion initiatives and the DG Media Network, while risks involve consumer spending sensitivity and competitive pressures. The current valuation at a P/E of 16.45 appears reasonable relative to historical performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →
